ONCAlert | Upfront Therapy for mRCC
Videos  >  

Highlighting a Current Challenge in Treating Patients With HCC

Kevin Staveley-O'Carroll, MD, PhD
Published Online:2:47 PM, Thu March 28, 2019

Kevin Staveley-O’Carroll, MD, PhD, surgery chair at the University of Missouri School of Medicine, and director of the Ellis Fischel Cancer Center, discusses one of the challenges in treating patients with hepatocellular carcinoma (HCC) and shares what he thinks are the next steps in overcoming this challenge.

Many different lines of therapy have been developed, but now the challenge lies in integrating these therapies properly in the treatment landscape of HCC, Staveley-O’Carroll says.

For example, by combining targeted kinase therapies with local ablative therapies, all of the dead tumor could be released, giving the patient the opportunity for more effective immunotherapy treatment.

See more from Dr. O’Carroll on the ongoing research at the University of Missouri.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.